Drug Trial Radar · NCT07859111
YJ001 Spray for Diabetic Peripheral Neuropathic Pain
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 3, 2026
Primary completion
Aug 30, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if YJ001 Spray works to treat diabetic patients with Diabetic Peripheral Neuropathic Pain..It will also learn about the safety of drug YJ001 Spray.This trial is divided into two parts. The first part of the trial is designed as a randomized, double-blind, double-dummy, parallel-controlled, multi-center clinical trial with positive reference product and placebo; the second part is designed as a single-arm, open-label, multi-center clinical trial.In the first part, the trial was divided into the test group, the positive control group, and the placebo group. In the first part,The experimental group received YJ001 spray + clobazam besylate capsule placebo, the positive control group received YJ001 spray placebo + clobazam besylate capsule, and the placebo group received YJ001 spray placebo + clobazam besylate capsule placebo. In the second part, all participants were treated with the investigational product, and 30 trial participants underwent PK blood sample collection according to the protocol. Part I of the trial : To evaluate the efficacy and safety of YJ001 spray in treating diabetic peripheral neuropathic pain. Part 2 of the trial: Evaluate the long-term efficacy and the pharmacokinetic characteristics of YJ001 spray in treating dia betic peripheral neuropathic pain at the clinically recommended dosage. Participants will: Apply spray topically to both feet twice daily, with six sprays per foot at each administration. Visit the clinic once every 1 or 2 or 4 weeks for checkups and tests Complete a study diary daily to record pain intensity, sleep interference, study-drug administration, and spray-related respiratory irritation.
Conditions
- Diabetic Peripheral Neuropathic Pain (DPNP)
Interventions
YJ001 spray simulantDrug
spray:0 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.
YJ001 sprayDrug
spray:480 mg/dose, once in the morning and once in the evening, 6 sprays per foot each time.
Crisugabalin Besilate CapsulesDrug
capsule:20mg per dose, twice a day
Crisugabalin Besilate Capsules simulantDrug
0mg per dose, twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Average Daily Pain Score (ADPS)Time frame: Week 12
- Number of participants with clinically significant changes in safety parameters from baselineTime frame: week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Institution
Beijing, Haidian District, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.